HK Stock Market Move | AKESO (09926) rises by nearly 6% as the global phase III HARMONi study on OS updates, showing highly consistent therapeutic effects in both Eastern and Western populations.

AKESO (09926) rose nearly 6%. As of the publication, it was up 5.86%, trading at 104.7 Hong Kong dollars, with a turnover of 6.48 billion Hong Kong dollars. On the news front, on July 22, AKESO's overseas partner Summit Therapeutics announced the latest OS analysis results of the global multicenter Phase III HARMONi study of AKESO. The results showed that the OS for the entire intention-to-treat (ITT) population continued to improve to HR=0.76, and the OS benefit for the Western population further increased to HR=0.76. This was highly consistent with the OS benefit of the previous HARMONi-A study in China. The median follow-up for the Western population was extended to 23.2 months, with continued improvement in benefits. Summit has submitted the updated data to the FDA to continue advancing AKESO's potential BLA application in the United States. CMSC believes that this data update not only validates AKESO's long-term immune benefits but also alleviates concerns about the unclear OS benefits for European and American patients and the possible inconsistency in results between Asian and Western populations. It represents a substantial de-risking of AKESO's global extrapolatability and provides positive support for the FDAPDUFA scheduled for November 14. The firm continues to favor AK112 from Kangfang as the next-generation cornerstone drug for IO therapy and expects overseas value realization. The updated OS follow-up data from HARMONi once again confirms that the benefits seen in the European and American populations can be replicated in the Chinese population.